I agree that this site is using cookies. You can find further informations
here
.
X
Login
My folder (
0
)
Home
About us
Home About us
Our history
Profile
Press & public relations
Friends
The library in figures
Exhibitions
Projects
Training, internships, careers
Films
Services & Information
Home Services & Information
Lending and interlibrary loans
Returns and renewals
Training and library tours
My Account
Library cards
New to the library?
Download Information
Opening hours
Learning spaces
PC, WLAN, copy, scan and print
Catalogs and collections
Home Catalogs and Collections
Rare books and manuscripts
Digital collections
Subject Areas
Our sites
Home Our sites
Central Library
Law Library (Juridicum)
BB Business and Economics (BB11)
BB Physics and Electrical Engineering
TB Engineering and Social Sciences
TB Economics and Nautical Sciences
TB Music
TB Art & Design
TB Bremerhaven
Contact the library
Home Contact the library
Staff Directory
Open access & publishing
Home Open access & publishing
Reference management: Citavi & RefWorks
Publishing documents
Open Access in Bremen
Show Desktop-Version
Toggle navigation
Fayette, Jérôme
171
results:
Search for persons
X
Format
Online (170)
Print (1)
Mediatypes
Books (1)
Articles (Online) (68)
Bookchapter (Online) (2)
OpenAccess-fulltext (100)
Languages
english (163)
french (1)
Sorted by: Relevance
Sorted by: Year
?
1
Cetuximab versus methotrexate in first-line treatment of ol..:
Guigay, Joël
;
Ortholan, Cécile
;
Vansteene, Damien
...
The Lancet Healthy Longevity. 5 (2024) 3 - p. e182-e193 , 2024
Link:
https://doi.org/10.1016/..
?
2
La cancérologie en Guyane : un défi à gagner:
Droz, Jean-Pierre
;
Couppié, Pierre
;
Fayette, Jérôme
Bulletin du Cancer. 111 (2024) 6 - p. 597-607 , 2024
Link:
https://doi.org/10.1016/..
?
3
Outcomes in biomarker-selected subgroups from the KESTREL s..:
Seiwert, Tanguy Y.
;
Wildsmith, Sophie
;
Fayette, Jérôme
...
Cancer Immunology, Immunotherapy. 73 (2024) 4 - p. , 2024
Link:
https://doi.org/10.1007/..
?
4
Adapted EXTREME regimen in the first-line treatment of fit,..:
Guigay, Joël
;
Le Caer, Hervé
;
Ferrand, François-Régis
...
The Lancet Healthy Longevity. 5 (2024) 6 - p. e392-e405 , 2024
Link:
https://doi.org/10.1016/..
?
5
Survival of bronchopulmonary cancers according to radon exp..:
Dessemon, Juliette
;
Perol, Olivia
;
Chauvel, Cécile
...
Frontiers in Public Health. 11 (2024) - p. , 2024
Link:
https://doi.org/10.3389/..
?
6
Uncovering immune checkpoint heterogeneity in oral squamous..:
Le Meitour, Yannick
;
Foy, Jean-Philippe
;
Guinand, Mathilde
...
Oral Oncology. 149 (2024) - p. 106680 , 2024
Link:
https://doi.org/10.1016/..
?
7
Comparison between exclusive (chemo)radiation and surgery o..:
Gauduchon, Coauthor(s) Thibault
;
Dalban, Cécile
;
Philippe, Zrounba
...
Oral Oncology Reports. 6 (2023) - p. 100042 , 2023
Link:
https://doi.org/10.1016/..
?
8
Efficacy of second-line chemotherapy or immune checkpoint i..:
Vienne, Agathe
;
Collet, Laetitia
;
Chevalier, Thomas
...
BMC Cancer. 23 (2023) 1 - p. , 2023
Link:
https://doi.org/10.1186/..
?
9
CTIM-32. A PARALLEL COHORT PHASE 2 STUDY OF REGORAFENIB PLU..:
Simonelli, Matteo
;
Caccese, Mario
;
Larrieu-Ciron, Delphine
...
Neuro-Oncology. 25 (2023) Supplement_5 - p. v69-v70 , 2023
Link:
https://doi.org/10.1093/..
?
10
Randomized phase II study of preoperative afatinib in untre..:
Marret, Grégoire
;
Temam, Stéphane
;
Kamal, Maud
...
Scientific Reports. 13 (2023) 1 - p. , 2023
Link:
https://doi.org/10.1038/..
?
11
NISCAHN: a phase II trial of nivolumab in patients with sal..:
Fayette, Jérôme
;
Even, Caroline
;
Digue, Laurence
...
BMJ Oncology. 2 (2023) 1 - p. e000065 , 2023
Link:
https://doi.org/10.1136/..
?
12
Occupational asbestos exposure and survival among lung canc..:
Noelle, Hugo
;
Pérol, Olivia
;
Pérol, Maurice
...
Lung Cancer. 179 (2023) - p. 107182 , 2023
Link:
https://doi.org/10.1016/..
?
13
Tumor Mutational Burden as a Predictor of Survival with Dur..:
Wildsmith, Sophie
;
Li, Weimin
;
Wu, Song
...
Clinical Cancer Research. 29 (2023) 11 - p. 2066-2074 , 2023
Link:
https://doi.org/10.1158/..
?
14
Long-term Outcomes with Nivolumab as First-line Treatment i..:
Gillison, Maura L
;
Blumenschein Jr, George
;
Fayette, Jerome
...
The Oncologist. 27 (2022) 2 - p. e194-e198 , 2022
Link:
https://doi.org/10.1093/..
?
15
Addendum: Hyperprogression and impact of tumor growth kinet..:
Karabajakian, Andy
;
Garrivier, Thibaut
;
Crozes, Carole
...
Oncotarget. 13 (2022) 1 - p. 1305-1305 , 2022
Link:
https://doi.org/10.18632..
1-15